Refoxy Pharmaceuticals

Executive Summary

Refoxy Pharmaceuticals GmbH is a pre-clinical biotech company headquartered in Munich, Germany, dedicated to developing therapies that target FOXO3 to treat aging-associated diseases. Leveraging its proprietary F.act finder discovery platform, the company aims to restore cellular balance and address conditions linked to aging. Founded in 2018, Refoxy operates in the small molecules category and remains privately held. As a pre-clinical entity, the company has not disclosed any funding rounds or partnerships, and its programs are in early-stage research. The platform's ability to identify novel FOXO3 modulators represents a potentially differentiated approach in the longevity space, but significant technical and regulatory hurdles remain. Validation through preclinical studies and securing capital are critical near-term milestones. The company's progress will depend on demonstrating efficacy and safety in animal models, followed by IND-enabling activities. Given the early stage and lack of disclosed financial backing, the risk profile is high, but the therapeutic potential in aging-related diseases warrants attention.

Upcoming Catalysts (preview)

• Q3 2026Completion of lead optimization for FOXO3 program40% success
• H2 2026Presentation of preclinical data at a major scientific conference60% success
• 2026Securing Series A financing30% success